TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06500676: An Open-Label, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of GFH375 in Patients With KRAS G12D Mutant Advanced Solid Tumors

Sponsor: Genfleet Therapeutics (Shanghai) Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 407 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$12,095,160

Rescue Site Savings

+$7,971,810

Unlock Full NCT06500676 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06500676 Rescue Dossier →